Introduction
Cyclic AMP (cAMP) is a ubiquitous second messenger that affects nearly every cell function from the maturation of the egg, to cell division and growth, differentiation and, ultimately, cell death.
Produced in response to a myriad of extracellular signals that activate receptors coupled to G proteins stimulatory for adenylyl cyclase (Gs), cAMP triggers a wide range of cellular responses through activation of protein kinase A (PKA), GTP exchange protein activated by cAMP (EPAC), cyclic nucleotide-gated (CNG) channels, and cyclic nucleotide phosphodiesterases (PDEs). In addition to the well established intracellular roles of cAMP, it has long been known that cAMP is extruded from a variety of cells, including erythrocytes, hepatocytes, endothelial and epithelial cells, neuronal cells and fibroblasts (Hofer and Lefkimmiatis, 2007) . Efflux of cAMP is due to active, ATP-dependent transport mediated by several multidrug resistance proteins (MRPs) including MRP4 (ABCC4), MRP5 and MRP8 (Hofer and Lefkimmiatis, 2007; Russel et al., 2008; Sampath et al., 2002; Wielinga et al., 2003) . MRPs represent a subfamily of ATP-binding cassette (ABC) transporters that were first identified by their ability to promote cellular resistance to anti-retroviral and anti-cancer drugs by mediating the cellular efflux of these compounds, hence the name for this group of transporters. In addition to cyclic nucleotides, MRPs efflux a remarkably wide range of other endogenous metabolites and signaling molecules including prostaglandins, leukotrienes, ADP, urate, steroids, glutathione, and bile salt, suggesting a potential role of MRPs in a multitude of physiological and pathophysiological processes (Hofer and Lefkimmiatis, 2007; Russel et al., 2008; Sampath et al., 2002) .
Although first described almost 50 years ago (Davoren and Sutherland, 1963) , the physiological significance of cellular cAMP efflux has yet to be fully understood. A role for cAMP as an extracellular signaling molecule, although well established in Dictyostelium (Kessin, 2001) , is controversial in mammals as extracellular cAMP receptors have not been conclusively identified (Bankir et al., 2002; Hofer and Lefkimmiatis, 2007) . However, as cAMP can be metabolized to adenosine in the extracellular space, extruded cAMP may serve as a "third messenger" that couples increased intracellular cAMP levels This article has not been copyedited and formatted. The final version may differ from this version. to stimulation of adenosine receptors in the so called "extracellular cAMP/adenosine pathway" (Hofer and Lefkimmiatis, 2007; Jackson and Raghvendra, 2004) .
In addition to an extracellular role of cAMP, cyclic nucleotide efflux may have a function in lowering intracellular levels of this second messenger. This idea had been previously discounted given the efficiency of intracellular cAMP degradation by PDEs compared to the low affinity of MRPs for cAMP (Reid et al., 2003a; Wielinga et al., 2003) . However, several studies investigating cAMP efflux have demonstrated an effect of acute MRP inactivation on whole-cell intracellular cAMP levels (Hofer and Lefkimmiatis, 2007; Li et al., 2007) . Moreover, biochemical, electrophysiological, and imaging studies using recently developed live cell cAMP sensors have now clearly established that cAMP signaling is compartmentalized and is restricted into so called "cAMP microdomains". While the properties of these cAMP microdomains remain to be defined in more detail, there is robust evidence that cAMP signaling in two subcellular compartments, the submembrane space (as detected using cAMP-gated ion channels or plasma membrane-targeted FRET-based cAMP sensors) and the cytosolic pool of cAMP (as detected by radioimmunoassays or cytosolic FRET-based cAMP sensors), behave distinctly from one another and that exchange between the two cAMP pools is restricted (Blackman et al., 2011; Huang et al., 2001; Rich et al., 2001; Terrin et al., 2006) . In light of this compartmentalization of cAMP signaling at the cell membrane, it is feasible that MRP-mediated cAMP efflux plays a critical role in the regulation of a small pool of submembrane cAMP which is not reflected in changes of whole-cell cAMP levels as it represents only a small fraction of the total cAMP present in the cell. Indeed, a role of MRP4 in regulating a submembrane cAMP pool has recently been proposed for intestinal epithelial cells (Li et al., 2007) .
MRP4 physically associates in a macromolecular signaling complex with the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-stimulated anion channel that is critical for transepithelial ion and water homeostasis. Pharmacologic or genetic inactivation of MRP4 or its displacement from the CFTR signaling complex results in increased levels of cAMP in the vicinity of the CFTR detectable as a PKA-dependent stimulation of CFTR function. This article has not been copyedited and formatted. The final version may differ from this version. In the present study, we used distinct model systems, including T84 epithelial cells and genetic models of MRP4 ablation or MRP4 overexpression, to dissect the role of MRPs on local and global intracellular cAMP signals.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Materials.
Cardiogreen (4,5-benzoindotricarbocyanine), adefovir (9-(2[bis(Pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine) and probenecid (4-(Dipropylsulfamoyl)benzoic acid) were from 
trifluoromethyl)phenyl-4-thiazolidinone) was a gift from Dr. A.S. Verkman (University of California San Francisco) (Ma et al., 2002) . The following antibodies were used in this study: Phospho(S157)-VASP and PKA substrate (Cell Signaling), α -tubulin (Sigma-Aldrich), MRP4 and VASP (Santa Cruz Biotechnology), and Shank2 (UC Davis/NIH NeuroMab Facility through Antibodies Incorporated, Davis, CA). PDE4 subtype-selective antibodies against PDE4A, PDE4B and PDE4D have been described previously (Richter et al., 2008) . CFTR antibodies (Cui et al., 2007) were kindly provided by Dr. J.R.
Riordan (University of North Carolina at Chapel Hill) through the CFTR Antibody Distribution Project managed by the Cystic Fibrosis Foundation. Wild type and MRP4-knockout mouse embryonic fibroblast cell lines derived from littermate embryos (Lin et al., 2008) were kindly provided by Dr. Alan C.
Sartorelli (Yale University School of Medicine, New Haven, CT) and Hek293 cell lines stably overexpressing MRP4 as well as control Hek293 cells (Wielinga et al., 2003) were cultured in DMEM supplemented with 10% FBS, 1 mM glutamine, 30 µg/ml penicillin, and 100 µg/ml streptomycin. All cells were cultured at 37°C and under a 5% CO 2 atmosphere. To induce quiescence, cells were routinely cultured in serum-free medium for 16 h before experimentation.
Short Circuit Current (I sc ) Measurements.
T84 cells were grown on 1.12 cm 2 Snapwell inserts (Corning). The filters were mounted into Ussing chambers and bathed in buffer containing 5 mM HEPES (pH 7.4), 25 mM NaHCO 3 , 120 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , and 10 mM D-glucose. The buffer was aerated with a mix of 95% O 2 and 5% CO 2 and temperature was kept at 37°C throughout the experiment. The cultures were voltageclamped at 0 mV using an EVC4000 MultiChannel V/I Clamp (World Precision Instruments). After a 30-min stabilization period, adenosine or CFTR inh -172 were added to the apical side at the specified times while the short-circuit current (I sc ) was continuously recorded.
IP of PDE4 Subtypes from Cell Extracts.
Cells were harvested in buffer containing 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 0.2 mM EGTA, 150 mM NaCl, 1.34 mM β -mercaptoethanol, 10% glycerol, 1 µM microcystin-LR, Complete protease inhibitor cocktail (Roche Diagnostics), and 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF; Roche Diagnostics). Cell debris was pelleted with a 30-min centrifugation at 20,000 g, and soluble extracts were immunoprecipitated using 30 µl ProteinG Sepharose and the respective PDE4 subtype antibody or normal IgG as a control. After incubation for 2 h at 4°C, the resin was washed three times and PDE recovered in the IP pellet was detected by PDE activity assay or Western blotting.
PDE Activity Assay.
PDE activity was measured as described previously (Richter and Conti, 2002) . Subtype-specific PDE activities were defined as the fraction of PDE activity inhibited by 20 µM vinpocetine (PDE1; (3α,16α)-This article has not been copyedited and formatted. The final version may differ from this version. quinolyloxy)butyramide), 10 µM rolipram (PDE4; 4-(3-(Cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one) or 100 nM sildenafil (PDE5; 1- [3] [4] 
Adenylyl Cyclase Activity Assay.
Adenylyl cyclase activity was measured as described previously (Jaiswal and Conti, 2001 ).
In vitro Phosphorylation Assay.
Cytosolic extracts prepared from quiescent T84 cell cultures were incubated for 5 min at 33°C with 0.2 mM ATP and 2 mM MgCl 2 . To induce PKA phosphorylation of VASP, 10 µM cAMP and 200 µM IBMX (3-isobutyl-1-methylxanthine) were added to some reactions.
Measurement of cAMP Accumulation.
Cell cultures were washed three times with PBS and incubated in serum-free medium overnight. The medium was exchanged once more 1 h before cell treatment. After the appropriate cell treatment, the extracellular (in some cases apical) fluid was removed and boiled for 5 min to inactivate cAMP hydrolases. The cell layer was washed with ice-cold PBS and 0.8 ml of 95% ice-cold ethanol containing 0.1% trichloroacetic acid (TCA) was then added to each well. After a 30-min incubation of the plates on ice the TCA solution containing the cAMP was collected. Cyclic AMP concentrations in extracellular and intracellular cAMP solutions were determined by radioimmunoassay (RIA) as previously described (Jaiswal and Conti, 2001 ). The cell protein, which remains on the cell culture plates/filters, was dissolved in 300 µl of 1 N NaOH per well, and this solution was used for determination of protein content.
This article has not been copyedited and formatted. The final version may differ from this version. T84 cells grown on collagen-coated glass coverslips were infected with an adenovirus encoding cAMP-EPAC2-PM (Wachten et al., 2010) at an MOI of 100. After overnight culture, cells were serum-starved in serum-free medium for 16 h. For FRET microscopy, coverslips were placed in a modified Sykes-Moore
Chamber and kept in 300 μl of Locke's medium (5 mM HEPES (pH 7.2), 154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl 2 , 1.0 mM MgCl 2 , 3.6 mM NaHCO 3 , 5 mM glucose, 0.05% BSA) at 37°C. Images were acquired with a Nikon TE2000 inverted fluorescence microscope using a 100x fluorescence objective.
CFP (donor) fluorescence was viewed by exciting at 430-455 nm and measuring emission at 470-490 nm.
YFP (acceptor) fluorescence was viewed by exciting at 500-520 nm and measuring emission at 535-565 nm. FRET was viewed by exciting at 430-455 nm (donor excitation) and measuring fluorescence at 535-565 nm (acceptor emission). Background and bleedthrough were subtracted from FRET images to obtain corrected FRET images using MetaMorph software (Molecular Devices). Average FRET intensity was measured directly in the corrected FRET images and the decrease in FRET as a result of elevated cAMP levels was calculated as % of FRET in untreated cells.
Mathematical Simulations and Statistical Analysis.
Simulations were performed using the fourth order Runge-Kutta solver in the MATLAB programming environment. Model details are presented in the Supplementary Material. Data were analyzed using oneway analysis of variance followed by Newman-Kuels post-hoc test, or regression analysis as appropriate.
Data analysis was performed using GraphPad Prism software.
This article has not been copyedited and formatted. The final version may differ from this version. As an initial characterization of cAMP efflux, cultures of non-polarized T84 cells were stimulated for 5 min with adenosine (ADO), prostaglandin E2 (PGE2) or the adenylyl cyclase activator forskolin (FSK) and extracellular and intracellular cAMP levels were measured by radioimmunoassay (RIA). Untreated cells did not efflux cAMP at levels detectable by RIA during the time span of the experiment. Conversely, treatment with ADO, PGE2 or FSK triggered a substantial increase in extracellular cAMP levels (Fig.   1A ). However, the amount of cAMP effluxed from the cells is minor when compared to the level of intracellular cAMP accumulated during the same time period (Fig. 1B) . Extracellular cAMP represents ~4 % of the intracellular cAMP. This ratio of extracellular to intracellular cAMP levels is independent of the total amount of cAMP produced ( Together, these results suggest that intracellular cAMP levels represent the equilibrium between cAMP production and a rapid degradation (see effect of the PDE4 inhibitor rolipram in Fig. 1F ), whereas extracellular cAMP levels simply represent accumulation of extruded cAMP. As a result, extracellular cAMP levels can reach or exceed intracellular cAMP levels of cells over long time courses despite the fact that the rate of cAMP extrusion from cells is slow compared to either production or intracellular degradation of cAMP ( Fig. 2E ).
PKA-phosphorylation of VASP or CFTR Reveals cAMP Signaling in a Submembrane
Compartment.
A recent report (Li et al., 2007) suggested that inactivation of cAMP efflux by MRP4 has an impact on intracellular cAMP levels only when cAMP levels are low, such as under basal conditions or upon treatment with low agonist concentrations, whereas MRP-inactivation does not have a significant effect on cAMP levels when cAMP production is maximally stimulated such as upon treatment with high agonist concentrations or FSK. Apical application of low concentrations of GPCR agonists, such as 1 µM ADO, substantially increases cAMP in a submembrane compartment of T84 cells that is revealed in the PKA-mediated activation of CFTR-dependent short-circuit currents ( Supplementary Fig. 2B ).
This article has not been copyedited and formatted. The final version may differ from this version. with actin-like filaments, focal adhesions and highly active regions of the plasma membrane, and its phosphorylation by PKA at Ser157 is well established (Smolenski et al., 1998) . We have shown recently, that PKA-phosphorylation of VASP is controlled by a submembrane pool of cAMP that is distinct from global cellular cAMP levels in mouse embryonic fibroblasts (Blackman et al., 2011) . In polarized T84
cells, VASP phosphorylation is significantly increased upon apical application of as little as 1 µM ADO compared to mock-treated cells. Thus, PKA phosphorylation of both VASP or CFTR represent suitable readouts for studying cAMP signaling in a submembrane pool at low agonist concentrations.
MRP Inhibitors Increase Submembrane cAMP Levels.
Next, we used the PKA-phosphorylation of VASP as a readout to study the effect of MRP inhibition on submembrane cAMP levels. Treatment with the MRP inhibitor probenecid (PB; 1 mM) did not significantly potentiate PKA phosphorylation of VASP in the presence of 2 µM ADO (Fig. 3 ).
Conversely, a substantial increase of VASP-phosphorylation was observed upon treatment with the MRP inhibitor MK571 at concentrations ≥ 30 µM. However, the dose-dependent effect of MK571 on VASP phosphorylation does not corroborate a blockade of MRP-dependent cAMP extrusion as the exclusive mechanism of action. As shown in Fig. 1D , MK571 blocks FSK-stimulated cAMP efflux from T84 cells with an IC 50 of 9.1 ± 2 µM. However, a significant effect of MK571 on VASP phosphorylation is observed only at significantly higher doses of MK571 (Fig. 3 ). The same effect was observed when the PKA-mediated phosphorylation of CFTR was used as a read-out for cAMP signaling in the apical submembrane compartment ( Supplementary Fig. 3 ). The observation that probenecid or low This article has not been copyedited and formatted. The final version may differ from this version. Fig. 4 ) and may, thus, act by increasing submembrane cAMP levels. To test this hypothesis, we utilized a plasma membrane-targeted cAMP sensor (cAMP-EPAC-PM) which is based on the cAMP effector GTPexchange protein activated by cAMP (EPAC) and has been reported previously (Wachten et al., 2010) .
The sensor is a chimera in which a fluorescence donor (CFP) and acceptor (YFP) are fused to EPAC.
Excitation of CFP produces FRET when cAMP levels are low and the EPAC moiety of the sensor is unoccupied. Binding of cAMP to the sensor alters its conformation resulting in a reduction in FRET.
When expressed in T84 cells, the sensor localizes to the plasma membrane (Fig. 3B, top) . Treatment of cAMP-EPAC-PM expressing cells with 20 µM MK571 resulted in a small but not significant change in FRET that may be indicative of an increase in submembrane cAMP levels. However, increasing the dose of MK571 to 100 µM produced a substantial elevation of cAMP as indicated by the further reduction in FRET. This confirms that MK571 further increases cAMP levels in the submembrane compartment at concentrations higher than those required to inhibit cAMP efflux and suggests an MRP-independent mechanism. Aside from cAMP efflux, MK571 may affect intracellular cAMP levels through stimulation of adenylyl cylcase or inhibition of cAMP degradation by PDEs. Experiments performed twice indicated that MK571 (100-300 µM) did not stimulate adenylyl cyclase activity in in vitro assays (data not shown).
However, MK571 significantly inhibited cAMP hydrolysis at these concentrations ( Supplementary Fig.   5A ).
Drugs Targeting MRPs Are Potent PDE Inhibitors.
This article has not been copyedited and formatted. The final version may differ from this version. T84 cells express a pattern of different PDE subtypes with PDE3 and PDE4 contributing the major portion of the total PDE activity measured at 1 µM cAMP (Fig. 4A ). MK571 dose-dependently inhibited total cAMP-PDE activity in T84 cell extracts with an IC 50 of 50 ± 5 µM (Fig. 4B ). PDE4D has been suggested to play a critical role in regulating cAMP signaling at the apical membrane of epithelial cells (Barnes et al., 2005; Lee et al., 2007) and recombinant PDE4D9 was inhibited by MK571 with an IC 50 of 45 ± 11 µM measured at 1 µM cAMP (Fig. 4B) . A kinetic analysis revealed that increasing concentrations of MK571 have no effect on the V max of recombinant PDE4D but increase the apparent k m of the enzyme (data not shown), thus suggesting that MK571 acts as a competitive inhibitor of cAMP hydrolysis by PDEs. As a consequence, the drug blocks cAMP hydrolysis more efficiently at lower substrate concentrations as confirmed by the lower IC 50 of 18.2 ± 1 µM for recombinant PDE4D9 when measured at 0.1 µM cAMP (Fig. 4B) . Inhibition of cAMP-PDE activity is not restricted to the MRP inhibitor MK571, but is a property common to this group of drugs. Adefovir, cardiogreen and probenecid, which are all used at a concentration of 1 mM to inhibit MRP-dependent transport, also inhibited cAMP-PDE activity in T84 cell extracts at this concentration, with Adefovir having the most predominant and probenecid having only a limited effect. As MRPs have also been implicated in the regulation of intracellular cGMP levels (see (Sager, 2004) for a review), we tested whether MRP inhibitors may also affect cGMP-PDE activity. PDE5 and PDE3 are the major PDE subtypes hydrolyzing cGMP in T84 cells and MK571 inhibited T84 cGMP-PDE activity with an IC 50 of 11 ± 4 µM measured at a substrate concentration of 0.1 µM cGMP. These data suggest that treatment with MRP inhibitors may affect intracellular cyclic nucleotide levels not only by blocking cyclic nucleotide extrusion, but also by inhibiting intracellular cyclic nucleotide degradation.
MRP-independent Augmentation of Intracellular cAMP Levels by 20 µM MK571 in Mouse Embryonic Fibroblasts (MEFs).
MK571 is widely used at a concentration of 20 µM to block MRP-dependent transport. To probe whether MK571 could exert a significant effect on global intracellular cAMP levels through partial inactivation of ISO-induced cAMP levels (Fig. 5) . Conversely, stimulation of T84 cells with 100 µM ADO (Fig. 1F) increases cAMP to much higher levels, thus limiting the effectiveness of MK571 as a competitive PDE inhibitor, and PDE inhibition is less potent in further elevating cAMP levels compared to the MEF model (see effect of Rolipram on ADO-induced cAMP levels in Fig. 1F) . Thus, the effectiveness of 20 µM MK571 in increasing global intracellular cAMP levels through partial inactivation of PDE activity may depend on the properties of the cAMP stimulus and the model cell. That treatment with MK571 increases total cellular cAMP levels as detected by radioimmunoassays (Fig. 5) suggests that its effects are not limited to increasing cAMP levels in microdomains of signaling at the cell membrane; a finding in line with the idea that inhibition of PDE activity is the mechanism of action of MK571.
Genetic Manipulation of MRP4 Expression Triggers Concomitant Changes in PDE Protein
and Activity.
Given the limited selectivity of established MRP inhibitors for inactivating cAMP efflux over cAMP degradation, we wished to utilize the genetic approach to probe the role of MRPs in controlling intracellular cAMP levels. To this end, we analyzed mouse embryonic fibroblasts (MEFs) deficient in MRP4 which have been shown to exhibit elevated intracellular cAMP levels compared to wild type control cells. Because MRP4 deficiency has been shown to result in lower expression levels of PKA in these cells (Lin et al., 2008) , we tested whether the PKA-mediated activation of PDE4, an important This article has not been copyedited and formatted. The final version may differ from this version. Fig. 6A ). However, total PDE activity in MRP4KO-MEFs is reduced to about 70 % of the activity in wild type cells independent of cell treatment ( Fig. 6A; Supplementary Figs. 6A/B) . PDE4 contributes the majority of total PDE activity in MEFs (Fig. 6A) . Of the four PDE4 subtypes, PDE4A-PDE4D, present in mammals, PDE4A and PDE4D
are the major subtypes expressed in MEFs ( Supplementary Fig. 6C ), and protein expression levels for This suggests that it is the loss of MRP-dependent transport, rather than differences in genetic background, that trigger altered PDE expression levels between WT and MRP4KO-MEFs. The reduction in PDE4 expression is also not due to increased intracellular cAMP levels resulting from PDE inhibition by MK571, because treatment with the PDE4 inhibitor Rolipram (10 µM) does not produce the same effect. This suggests that the reduced PDE4 expression results from inactivation of the MRP4-dependent transport of other signaling molecules. PGE2 represents a good candidate for such a molecule as it is efficiently transported by MRP4 (Reid et al., 2003b) and extracellular PGE2 levels in MRP4KO-MEF cultures are reduced to ~25% of that in wild type controls (Lin et al., 2008) . A 20 h treatment with 10 µM PGE2 increased cAMP-PDE activity levels in both wild type and MRP4KO-MEFs ( Supplementary Fig.   7A ). The increase in PDE activity in PGE2-treated compared to mock-treated cells is more pronounced in MRP4KO-MEFs (29±4 % stimulation) compared to wild type cells (11±2.5 % stimulation), thus reducing the difference in cAMP-PDE activity levels between wild type and MRP4KO-MEFs. This suggests that PGE2 is likely one, but clearly not the only molecule, whose cellular extrusion by MRP4 is required for normal PDE expression levels. Along the same line, treatment with the adenylyl cyclase (AC) inhibitor This article has not been copyedited and formatted. The final version may differ from this version. Fig. 7B ).
In opposite to the effect of MRP4 inactivation on PDE expression, we found that Hek293 cells stably overexpressing MRP4 (Wielinga et al., 2003) express higher levels of total PDE activity compared to control cells (Fig. 6D-F) . PDE4 is the major PDE subtype expressed in Hek293 cells and is primarily responsible for the increase in total PDE activity in MRP4-overexpressing Hek293 cells (Fig. 6E ).
PDE4D is the major PDE4 subtype expressed ( Supplementary Fig. 8 ), and an increase in protein expression levels of PDE4D (Fig. 6F ) mimics the effect of MRP4-overexpression on total and PDE4-specific PDE activity (Fig. 6E ).
Taken together, these data demonstrate that both genetic manipulation of MRP4 expression or long-term pharmacological MRP inactivation can produce concomitant changes in PDE expression. Thus, the effect of manipulating MRP expression and/or activity on intracellular cAMP signaling in these model systems cannot be solely attributed to altered cAMP extrusion, as parallel changes in PDE expression also impact intracellular cAMP levels (Fig. 8 ).
Mathematical Modeling of the Effects of an MRP-specific Inhibitor on Global and
Submembrane cAMP Signals.
As both genetic and pharmacologic inactivation of MRPs also affect cAMP degradation by PDEs, it is difficult to determine experimentally if, and to what extent, the selective inactivation of MRP-dependent cAMP extrusion might control intracellular cAMP levels. To explore the possible scenarios, we used a mathematical modeling approach. In a first set of simulations, we probed a two-compartment model ( μ M MK571 triggers a ~20% increase in intracellular cAMP levels due to partial inactivation of PDE activity (data not shown).
As cAMP signaling is thought to be compartmentalized, we next probed the idea that MRPs could regulate cAMP levels in a small submembrane compartment from which cAMP is extruded by MRPs into the extracellular space but which does not rapidly exchange cAMP with the global cytosolic pool of cAMP. To this end, a three-compartment model consisting of a global/cytosolic intracellular cAMP compartment (I-C), a second intracellular compartment restricted to the submembrane space (I-SM), and the extracellular compartment was generated (Fig. 7D) . The submembrane compartment I-SM was defined as 1% of the size of the cytosolic pool of cAMP (I-C) and contains all cellular MRP activity but only a fraction (0.1%) of total PDE activity. Moreover, cAMP diffusion between the two intracellular compartments with the rate J I-SM/I-C is greatly reduced compared to estimates of free diffusion of cAMP (>10 -6 cm 2 /s) as could be achieved through physical barriers such as membrane invaginations (Rich et al., 2001 ). Similar to findings with the two-compartment model, simulation of treatment with a selective MRP-inhibitor ablates cAMP efflux from the submembrane compartment I-SM into the extracellular space E (data not shown) but has no significant effect on the global cytosolic pool of cAMP I-C (Fig. 7E) .
However, selective inactivation of MRP-dependent efflux significantly increases cAMP levels in the restricted submembrane space I-SM (Fig. 7F) suggesting that MRPs may control cAMP signaling in microdomains of signaling at the cell membrane.
Mutually Exclusive Interactions of CFTR with PDZ scaffold proteins that sequester PDEs or MRPs.
Our mathematical simulations suggest that MRPs may play a role in the regulation of submembrane cAMP signals only in microdomains of signaling that are highly enriched in MRP activity, but not PDE This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 7) . This raises the question of how such microdomains could be organized, given the observation that PDE activity is also enriched at the apical membrane of epithelial cells (Barnes et al., 2005; Lee et al., 2007) . Here we explored whether the interaction of CFTR with distinct PDZ scaffold proteins might create microdomains of signaling in epithelial cells. Shank2 has been previously identified as a scaffold protein tethering PDE activity to the CFTR (Lee et al., 2007) , whereas the PDZ scaffold PDZK1 can sequester MRP4 to the CFTR signaling complex (Li et al., 2007) . As CFTR, through its Cterminal PDZ binding domain, can only interact with one PDZ scaffold protein at a time, sequestration of CFTR in complex with Shank2/PDE might create a microdomain of signaling high in PDE activity but low in MRP activity, whereas interaction of CFTR with PDZK1/MRP4 may provide the opposite environment. Indeed, co-IP experiments suggest that the interaction of CFTR with PDEs and MRP4 is mutually exclusive. Both CFTR and Shank2 co-immunoprecipitate PDE activity from T84 epithelial cells whereas MRP4 does not ( Supplementary Fig. 9 ). In addition, CFTR and Shank2 interact with PDEs in overexpression systems (Lee et al., 2007; Penmatsa et al., 2010) , whereas exogenous PDE4s do not co-
immunoprecipitate MRP4 from MRP4-overexpressing Hek293 cells (data not shown).
Discussion
Since MRPs were originally identified as mediators of cellular cAMP and cGMP efflux (Jedlitschky et al., 2000; Wielinga et al., 2003) an increasing number of studies have reported augmented intracellular levels of these second messengers in response to MRP inactivation and important biological functions of cyclic nucleotide extrusion in various cell types (Andric et al., 2006; Li et al., 2007; Lin et al., 2008; Sassi et al., 2008) . The reported increases were assumed to be direct results of the ablation of cyclic nucleotide (Fig. 3A and Supplementary Fig. 3 ) or by real-time cAMP measurement with the cAMP-EPAC2-PM probe (Fig. 3B) suggest that MRP inactivation does not affect cAMP signaling in the submembrane compartment as a whole. Rather it may control microdomains of signaling that are too small to be detected with the methods applied in the present study. This hypothesis would be in agreement with the MRP-dependent regulation of CFTR proposed previously (Li et al., 2007) which depends on a macromolecular signaling complex that tethers MRP4 to CFTR via the PDZ scaffold protein PDZK1. CFTR interacts with a number of PDZ scaffold proteins (Li and Naren, 2005) .
Consequently, only a fraction of cellular CFTR protein is in complex with PDZK1 and, thus, in close proximity of MRP4 at any given time. Thus, while MRP4 might play a critical role in regulating this subpopulation of CFTR protein, the effect of MRP inactivation may not be detectable in assays measuring PKA phosphorylation levels of total cellular CFTR protein. Taken together, MRPs may control cAMP signaling in defined submembrane compartments. Elucidating the effect of MRP inactivation on intracellular cAMP levels in these microdomains will require probes that sense cAMP specifically in these compartments, novel tools that allow inactivation of MRPs without affecting cAMP degradation by PDEs and controls to exclude secondary effects caused by the ablation of MRP-dependent transport of other signaling molecules, such as prostaglandins (Hofer and Lefkimmiatis, 2007) .
Here, we report for the first time that a set of compounds commonly used to inhibit and define MRP functions are also potent inhibitors of phosphodiesterases. Given that both MRPs and PDEs bind cAMP and cGMP, it is conceivable that these proteins share some similarities in the spatial and electrochemical dependent transport complementing the present findings (de Wolf et al., 2007; Jedlitschky et al., 2000; Reid et al., 2003a; van Aubel et al., 2002; Wielinga et al., 2003) .
Comparing the time course of extracellular and intracellular cAMP accumulation in response to treatment of T84 cells with adenosine or forskolin (Figs. 1 and 2 ) reveals critical differences between their respective kinetics. Intracellular cAMP levels quickly plateau and subsequently return to basal levels, whereas extracellular cAMP levels continue to rise over extended time periods, a pattern that has also been observed in many other cell models (Andric et al., 2006; Biondi et al., 2010; Brunton and Mayer, 1979; Doore et al., 1975; Hamet et al., 1989; Penit et al., 1974) . The different patterns of cAMP accumulation result primarily from differences in the efficiency of cAMP degradation. Intracellular cAMP accumulation is quickly reversed by the action of phosphodiesterases whereas extracellular cAMP is not efficiently degraded, allowing accumulation over time. Thus, it is difficult to evaluate the efficiency of cAMP extrusion compared to intracellular cAMP turnover in cases when cAMP concentrations are reported only for single time points. The direct comparison of intra-and extracellular cAMP levels after a short-time stimulation (Fig. 1B) underscores the fact that the amount of cAMP extruded from cells is minor compared to the total amount of cAMP generated conforming the idea that MRP inactivation is unlikely to increase total intracellular cAMP levels in the presence of PDE activity. Conversely, as extracellular cAMP levels equal or exceed intracellular cAMP levels after long-term stimulations, their direct comparison at late time points may lead to the inaccurate conclusion that a large fraction of the intracellular cAMP was extruded from cells ( Fig. 2E ). Long-term stimulations do, however, better emphasize the fact that extracellular cAMP levels can reach significant levels supporting the idea of extracellular functions for extruded cAMP.
In our experimental setting, cAMP extruded from the cells is rapidly diluted into a large extracellular volume (1 ml/cell culture well) compared to the total volume of the cultured cells (~20 (Knecht et al., 1983) . Depending on the cell type, extracellular cAMP might be extruded into a much smaller volume, such as the interstitial space or the airway surface liquid (ASL) of lung epithelia (Thiagarajah et al., 2010) in vivo and might quickly reach micromolar concentrations. Thus, extracellular cAMP degradation might play a more significant role in the control of extracellular cAMP levels in vivo. Moreover, extracellular cAMP concentrations may locally reach or exceed the levels of intracellular cAMP which may explain why cAMP is extruded from cells through an ATP-dependent active transport mechanism that allows extrusion against a concentration gradient.
As shown in Fig. 6 , genetic inactivation of MRP4 or long-term treatment with MRP inhibitors results in downregulation of PDE protein and activity in MEFs, whereas overexpression of MRP4 triggers a parallel upregulation of PDE expression in Hek293 cells. That inhibition of MRP activity mimics the effect of ablation of protein expression suggests that it is the loss of MRP-dependent transport, rather than the absence of MRP4 protein per se, that triggers altered PDE expression. Thus, our findings identify MRPdependent transport as a novel determinant of cellular PDE expression levels. The exact mechanism by which MRP inactivation controls PDE expression remains to be determined. It should be noted, however, that MRPs efflux a large array of signaling molecules including the cyclic nucleotides themselves as well as prostaglandins and leukotrienes (Hofer and Lefkimmiatis, 2007; Russel et al., 2008) , whose extracellular signaling is mediated by the cAMP pathway, thus providing a reasonable explanation why inactivation of their cellular export triggers feedback mechanisms involving cAMP signaling proteins.
Indeed, MRP4-deficient MEFs exhibit reduced levels of extracellular PGE2 (Lin et al., 2008) and adding exogenous PGE2 to MEF cultures reduces the differences in PDE expression levels between wild type and MRP4KO cells (Supplementary Fig. 7A ). MRP4KO-MEFs also show reduced levels of basal adenylyl cyclase activity ( Supplementary Fig. 7B ) in line with idea that MRP4 ablation impairs the signaling of molecules that stimulate the cAMP pathway. Taken together, our findings imply that Table 2 . E/F, Also in the three compartment model, selective inactivation of MRPs has no effect on the bulk cytosolic pool of cAMP (I-C), but can augment cAMP levels in the submembrane compartment (I-SM) (F). (Poschet et al., 2007) , is efficiently effluxed by MRPs (de Wolf et al., 2007; Jedlitschky et al., 2000; van Aubel et al., 2002) , and its intracellular accumulation inhibits cAMPdegradation by PDE3 (Conti and Beavo, 2007) , a PDE subtype highly expressed in and enriched at the apical membrane of epithelial cells (Penmatsa et al., 2010) . 
